Jansitin

Sitagliptin, the active ingredient in Jansitin, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Jansitin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is a DPP‑4 inhibitor indicated for managing type 2 diabetes mellitus and related therapeutic pathways. - Type 2 diabetes mellitus: lowers blood glucose levels when used with diet and exercise. - Combination with metformin: provides additional reduction in HbA1c compared with metformin alone. - Combination with insulin: helps achieve target glycaemic control in patients requiring insulin therapy.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Upper respiratory infection: cough, sore throat, or congestion. - Nausea: occasional mild nausea. - Diarrhoea: loose stools that are usually self‑limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent. - Bullous pemphigoid: rare skin blistering disorder. - Hepatic injury: elevated liver enzymes or hepatitis.

Before initiating sitagliptin therapy, several safety considerations should be reviewed. - Renal impairment: assess renal function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and use with caution. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Cardiovascular disease: observe for any worsening of heart failure symptoms. - Pregnancy and lactation: limited data; prescribe only if potential benefit justifies risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Sitagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Sulfonylureas: increased risk of hypoglycaemia. - Insulin: additive glucose‑lowering effect may cause hypoglycaemia. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Rifampin: may decrease sitagliptin exposure, reducing efficacy. - Diuretics: altered renal clearance may affect drug concentration. - ACE inhibitors: monitor renal function when used together.